{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:45:21Z","timestamp":1791935121212,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04856-8","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:37:00Z","timestamp":1769762220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revolutionizing cancer treatment with senotherapeutics: a current perspective"],"prefix":"10.1007","volume":"96","author":[{"given":"Lakshika","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran Deep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Vihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-7548","authenticated-orcid":false,"given":"Deepak N.","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"4856_CR1","unstructured":"Cancer Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1"},{"key":"4856_CR2","unstructured":"Cancer Development | CancerQuest Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/cancerquest.org\/cancer-biology\/cancer-development"},{"key":"4856_CR3","unstructured":"Cancer Overview, causes, treatments, and types. Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.medicalnewstoday.com\/articles\/323648"},{"key":"4856_CR4","unstructured":"Cancer treatment - Mayo Clinic., Accessed Feb. 05, 2025. [Online]. Available: https:\/\/www.mayoclinic.org\/tests-procedures\/cancer-treatment\/about\/pac-20393344"},{"key":"4856_CR5","unstructured":"Cancer treatments MedlinePlus Medical Encyclopedia. Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/medlineplus.gov\/ency\/patientinstructions\/000901.htm"},{"key":"4856_CR6","unstructured":"Overview of Cancer Therapy - Hematology and Oncology - MSD Manual Professional Edition Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.msdmanuals.com\/professional\/hematology-and-oncology\/principles-of-cancer-therapy\/overview-of-cancer-therapy"},{"key":"4856_CR7","doi-asserted-by":"publisher","DOI":"10.3892\/OR.2022.8405","author":"R Naser","year":"2022","unstructured":"Naser R, Dilabazian H, Bahr H, Barakat A, El-Sibai M (2022) A guide through conventional and modern cancer treatment modalities: a specific focus on glioblastoma cancer therapy (Review). Oncol Rep. https:\/\/doi.org\/10.3892\/OR.2022.8405","journal-title":"Oncol Rep"},{"key":"4856_CR8","doi-asserted-by":"publisher","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY Exploring treatment options in cancer: tumor treatment strategies. Dec 01 2024 Springer Nature. https:\/\/doi.org\/10.1038\/s41392-024-01856-7","DOI":"10.1038\/s41392-024-01856-7"},{"key":"4856_CR9","doi-asserted-by":"publisher","unstructured":"Gorgoulis V et al (2019) Cellular Senescence: Defining a Path Forward, Oct. 31, Cell Press. https:\/\/doi.org\/10.1016\/j.cell.2019.10.005","DOI":"10.1016\/j.cell.2019.10.005"},{"key":"4856_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-01018-5","author":"K Czajkowski","year":"2024","unstructured":"Czajkowski K, Herbet M, Murias M, Pi\u0105tkowska-Chmiel I (2024) Senolytics: charting a new course or enhancing existing anti-tumor therapies. Springer Sci Bus Media B V. https:\/\/doi.org\/10.1007\/s13402-024-01018-5","journal-title":"Springer Sci Bus Media B V"},{"key":"4856_CR11","doi-asserted-by":"crossref","unstructured":"Hayflick L, Moorhead PS (1961) THE SERIAL CULTIVATION OF HUMAN DIPLOID CELL STRAINS\u2019","DOI":"10.1016\/0014-4827(61)90192-6"},{"issue":"1","key":"4856_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21926\/obm.geriatr.1901034","volume":"3","author":"M Fossel","year":"2018","unstructured":"Fossel M (2018) Cell senescence, telomerase, and senolytic therapy. OBM Geriat 3(1):1\u20131. https:\/\/doi.org\/10.21926\/obm.geriatr.1901034","journal-title":"OBM Geriat"},{"key":"4856_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084168","author":"N Kudlova","year":"2022","unstructured":"Kudlova N, De Sanctis JB, Hajduch M (2022) Cellular senescence: molecular targets, biomarkers, and senolytic drugs. MDPI. https:\/\/doi.org\/10.3390\/ijms23084168","journal-title":"MDPI"},{"key":"4856_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13312","author":"L Bousset","year":"2022","unstructured":"Bousset L, Gil J (2022) Targeting senescence as an anticancer therapy. Mol Oncol. https:\/\/doi.org\/10.1002\/1878-0261.13312","journal-title":"Mol Oncol"},{"key":"4856_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.07.002","author":"JW Zhang","year":"2021","unstructured":"Zhang JW, Zhang D, Yu BP (2021) Senescent cells in cancer therapy: why and how to remove them. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.002","journal-title":"Cancer Lett"},{"key":"4856_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2009.22","author":"ARJ Young","year":"2009","unstructured":"Young ARJ, Narita M (2009) SASP reflects senescence. EMBO Rep. https:\/\/doi.org\/10.1038\/embor.2009.22","journal-title":"EMBO Rep"},{"issue":"Special Issue 2","key":"4856_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.22159\/ajpcr.2018.v11s2.28563","volume":"11","author":"P Kaur","year":"2018","unstructured":"Kaur P et al (2018) Formulation, systematic optimization, in vitro, ex vivo, and stability assessment of transethosome based gel of curcumin. Asian J Pharm Clin Res 11(Special Issue 2):41\u201347. https:\/\/doi.org\/10.22159\/ajpcr.2018.v11s2.28563","journal-title":"Asian J Pharm Clin Res"},{"key":"4856_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13141","author":"JL Kirkland","year":"2020","unstructured":"Kirkland JL, Tchkonia T (2020) Senolytic drugs: from discovery to translation. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13141","journal-title":"J Intern Med"},{"key":"4856_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16350","author":"L Zhang","year":"2023","unstructured":"Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD (2023) Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. https:\/\/doi.org\/10.1111\/febs.16350","journal-title":"FEBS J"},{"issue":"4","key":"4856_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu Y et al (2015) The achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14(4):644\u2013658. https:\/\/doi.org\/10.1111\/acel.12344","journal-title":"Aging Cell"},{"key":"4856_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040723","author":"VJ Carpenter","year":"2021","unstructured":"Carpenter VJ, Saleh T, Gewirtz DA (2021) Senolytics for cancer therapy: is all that glitters really gold? Cancers. https:\/\/doi.org\/10.3390\/cancers13040723","journal-title":"Cancers"},{"key":"4856_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.958563","author":"C Lu\u00eds","year":"2022","unstructured":"Lu\u00eds C, Maduro AT, Pereira P, Mendes JJ, Soares R, Ramalho R (2022) Nutritional senolytics and senomorphics: implications to immune cells metabolism and aging \u2013 from theory to practice. Front Nutr. https:\/\/doi.org\/10.3389\/fnut.2022.958563","journal-title":"Front Nutr"},{"key":"4856_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13040076","author":"S Malayaperumal","year":"2023","unstructured":"Malayaperumal S et al (2023) The emerging role of senotherapy in cancer: a comprehensive review. Clin Pract. https:\/\/doi.org\/10.3390\/clinpract13040076","journal-title":"Clin Pract"},{"key":"4856_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw1299","author":"JM van Deursen","year":"2019","unstructured":"van Deursen JM (2019) Senolytic therapies for healthy longevity. Science. https:\/\/doi.org\/10.1126\/science.aaw1299","journal-title":"Science"},{"key":"4856_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13948","author":"H Power","year":"2023","unstructured":"Power H, Valtchev P, Dehghani F, Schindeler A (2023) Strategies for senolytic drug discovery. Aging Cell. https:\/\/doi.org\/10.1111\/acel.13948","journal-title":"Aging Cell"},{"key":"4856_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S469110","author":"Y Shi","year":"2024","unstructured":"Shi Y et al (2024) Advances in nanotherapy for targeting senescent cells. Int J Nanomedicine. https:\/\/doi.org\/10.2147\/IJN.S469110","journal-title":"Int J Nanomedicine"},{"key":"4856_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03746-x","author":"CSA Davan-Wetton","year":"2021","unstructured":"Davan-Wetton CSA, Pessolano E, Perretti M, Montero-Melendez T (2021) Senescence under appraisal: hopes and challenges revisited. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s00018-020-03746-x","journal-title":"Cell Mol Life Sci"},{"key":"4856_CR28","doi-asserted-by":"publisher","unstructured":"Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H, Niedernhofer LJ, Robbins PD, Tchkonia T,  Kirkland JL (2017) New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY, 9(3):955\u2013963. https:\/\/doi.org\/10.18632\/aging.101202","DOI":"10.18632\/aging.101202"},{"key":"4856_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.BCP.2023.115739","volume":"215","author":"R Billimoria","year":"2023","unstructured":"Billimoria R, Bhatt P (2023) Senescence in cancer: advances in detection and treatment modalities. Biochem Pharmacol 215:115739. https:\/\/doi.org\/10.1016\/J.BCP.2023.115739","journal-title":"Biochem Pharmacol"},{"key":"4856_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16649","author":"N Rachmian","year":"2023","unstructured":"Rachmian N, Krizhanovsky V (2023) Senescent cells in the brain and where to find them. FEBS J. https:\/\/doi.org\/10.1111\/febs.16649","journal-title":"FEBS J"},{"key":"4856_CR31","doi-asserted-by":"publisher","unstructured":"Riviere-Cazaux C et al (2023) An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence. NPJ Precis Oncol. https:\/\/doi.org\/10.1038\/s41698-023-00476-8","DOI":"10.1038\/s41698-023-00476-8"},{"key":"4856_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14037","author":"V Budamagunta","year":"2024","unstructured":"Budamagunta V et al (2024) Senolytic treatment alleviates doxorubicin-induced chemobrain. Aging Cell. https:\/\/doi.org\/10.1111\/acel.14037","journal-title":"Aging Cell"},{"issue":"23","key":"4856_CR33","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-23-0834","volume":"29","author":"M Johnson","year":"2023","unstructured":"Johnson M et al (2023) Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence. Clin Cancer Res 29(23):4973\u20134989. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0834","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4856_CR34","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s11357-023-00870-x","volume":"45","author":"R Gulej","year":"2023","unstructured":"Gulej R et al (2023) Elimination of senescent cells by treatment with Navitoclax\/ABT263 reverses whole brain irradiation-induced blood-brain barrier disruption in the mouse brain. Geroscience 45(5):2983\u20133002. https:\/\/doi.org\/10.1007\/s11357-023-00870-x","journal-title":"Geroscience"},{"issue":"4","key":"4856_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/neuonc\/noac199","volume":"25","author":"F Selt","year":"2023","unstructured":"Selt F et al (2023) BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro Oncol 25(4):735\u2013747. https:\/\/doi.org\/10.1093\/neuonc\/noac199","journal-title":"Neuro Oncol"},{"key":"4856_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab148","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M et al (2021) Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdab148","journal-title":"Neuro-Oncol Adv"},{"issue":"23","key":"4856_CR37","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1158\/0008-5472.CAN-21-0752","volume":"81","author":"E Fletcher-Sananikone","year":"2021","unstructured":"Fletcher-Sananikone E et al (2021) Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res 81(23):5935\u20135947. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0752","journal-title":"Cancer Res"},{"key":"4856_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071815","author":"M Milczarek","year":"2020","unstructured":"Milczarek M (2020) The premature senescence in breast cancer treatment strategy. Cancers. https:\/\/doi.org\/10.3390\/cancers12071815","journal-title":"Cancers"},{"key":"4856_CR39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0643","author":"B de Paula","year":"2023","unstructured":"de Paula B, Kieran R, Koh SSY, Crocamo S, Abdelhay E, Mu\u00f1oz-Esp\u00edn D (2023) Targeting senescence as a therapeutic opportunity for triple-negative breast cancer. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0643","journal-title":"Mol Cancer Ther"},{"key":"4856_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100841","author":"F T\u00f3th","year":"2024","unstructured":"T\u00f3th F, Moftakhar Z, Sotgia F, Lisanti MP (2024) In vitro investigation of therapy-induced senescence and senescence escape in breast cancer cells using novel flow cytometry-based methods. Cells. https:\/\/doi.org\/10.3390\/cells13100841","journal-title":"Cells"},{"key":"4856_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106628","author":"A Estepa-Fern\u00e1ndez","year":"2023","unstructured":"Estepa-Fern\u00e1ndez A et al (2023) Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2022.106628","journal-title":"Pharmacol Res"},{"key":"4856_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers","volume":"2022","author":"A Lew\u00ed Nska","year":"2022","unstructured":"Lew\u00ed Nska A, Przybylski P, Adamczyk-Grochala J, B\u0142oniarz D, Litwinienko G, Wnuk M (2022) Senolysis-based elimination of chemotherapy-induced senescent breast cancer cells by quercetin derivative with blocked hydroxy groups. Cancers (Basel) 2022:605. https:\/\/doi.org\/10.3390\/cancers","journal-title":"Cancers (Basel)"},{"key":"4856_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213047","author":"A Lewi\u0144ska","year":"2022","unstructured":"Lewi\u0144ska A, Wr\u00f3bel K, B\u0142oniarz D, Adamczyk-Grochala J, Wo\u0142owiec S, Wnuk M (2022) Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status. Biomater Adv. https:\/\/doi.org\/10.1016\/j.bioadv.2022.213047","journal-title":"Biomater Adv"},{"key":"4856_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119196","author":"D Yang","year":"2021","unstructured":"Yang D et al (2021) Identification of GL-V9 as a novel senolytic agent against senescent breast cancer cells. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2021.119196","journal-title":"Life Sci"},{"key":"4856_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395047","author":"MY Xu","year":"2024","unstructured":"Xu MY et al (2024) A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1395047","journal-title":"Front Immunol"},{"key":"4856_CR46","doi-asserted-by":"publisher","unstructured":"Fiard G et al (2021) Cellular senescence as a possible link between prostate diseases of the ageing male. Nat Rev Urol 18. https:\/\/doi.org\/10.1038\/s41585-021-00496-8","DOI":"10.1038\/s41585-021-00496-8"},{"key":"4856_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00422-2","author":"T Pungsrinont","year":"2020","unstructured":"Pungsrinont T et al (2020) Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells. Cell Biosci. https:\/\/doi.org\/10.1186\/s13578-020-00422-2","journal-title":"Cell Biosci"},{"key":"4856_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071593","author":"N Malaquin","year":"2020","unstructured":"Malaquin N et al (2020) DNA damage-but not enzalutamide-induced senescence in prostate cancer promotes senolytic bcl-xl inhibitor sensitivity. Cells. https:\/\/doi.org\/10.3390\/cells9071593","journal-title":"Cells"},{"issue":"1","key":"4856_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","volume":"39","author":"I Guccini","year":"2021","unstructured":"Guccini I et al (2021) Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell 39(1):68-82.e9. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.012","journal-title":"Cancer Cell"},{"key":"4856_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells11244026","author":"E Pardella","year":"2022","unstructured":"Pardella E et al (2022) Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer. Cells. https:\/\/doi.org\/10.3390\/cells11244026","journal-title":"Cells"},{"key":"4856_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126902","author":"C Han","year":"2023","unstructured":"Han C et al (2023) Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1126902","journal-title":"Front Immunol"},{"key":"4856_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01095-3","author":"R Alvarez-Arzola","year":"2023","unstructured":"Alvarez-Arzola R et al (2023) VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer. Cell Commun Signal. https:\/\/doi.org\/10.1186\/s12964-023-01095-3","journal-title":"Cell Commun Signal"},{"issue":"4","key":"4856_CR53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ccell.2024.02.004","volume":"42","author":"M Colucci","year":"2024","unstructured":"Colucci M et al (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer Cell 42(4):646-661.e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.004","journal-title":"Cancer Cell"},{"key":"4856_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00770","author":"SN Knoppert","year":"2019","unstructured":"Knoppert SN, Valentijn FA, Nguyen TQ, Goldschmeding R, Falke LL (2019) Cellular senescence and the kidney: potential therapeutic targets and tools. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00770","journal-title":"Front Pharmacol"},{"key":"4856_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14399","author":"IM Al-Naggar","year":"2024","unstructured":"Al-Naggar IM et al (2024) Polyploid superficial uroepithelial bladder barrier cells express features of cellular senescence across the lifespan and are insensitive to senolytics. Aging Cell. https:\/\/doi.org\/10.1111\/acel.14399","journal-title":"Aging Cell"},{"key":"4856_CR56","doi-asserted-by":"publisher","unstructured":"Kim SR et al (2021) Progressive cellular senescence mediates renal dysfunction in ischemic nephropathy, Journal of the American Society of Nephrology, vol. 32, no. 8, pp. 1987\u20132004, Aug. https:\/\/doi.org\/10.1681\/ASN.2020091373\/-\/DCSUPPLEMENTAL","DOI":"10.1681\/ASN.2020091373\/-\/DCSUPPLEMENTAL"},{"key":"4856_CR57","unstructured":"Missiaen R, Anderson N, Kim L, metabolism BN-C (2022) and undefined GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment, cell.comR Missiaen, NM Anderson, LC Kim, B Nance, M Burrows, N Skuli, M Carens, R RiscalCell metabolism, 2022\u2022cell.com, Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.cell.com\/cell-metabolism\/fulltext\/S1550-4131(22)00230-3"},{"issue":"1","key":"4856_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-79663-x","volume":"14","author":"S Zhou","year":"2024","unstructured":"Zhou S et al (2024) The deleterious effects of CDK4\/6 inhibition on renal recovery post-acute kidney injury. Sci Rep 14(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-024-79663-x","journal-title":"Sci Rep"},{"key":"4856_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44903-1","author":"S Rojas-V\u00e1zquez","year":"2024","unstructured":"Rojas-V\u00e1zquez S et al (2024) A renal clearable fluorogenic probe for in vivo \u03b2-galactosidase activity detection during aging and senolysis. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-024-44903-1","journal-title":"Nat Commun"},{"key":"4856_CR60","unstructured":"C. Liao, V. Wulfmeyer, R. Chen, \u2026 Z. E.-A. J. of, and undefined 2022, Induction of ferroptosis selectively eliminates senescent tubular cells, Elsevier, Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1600613522299109"},{"issue":"5","key":"4856_CR61","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1164\/rccm.201810-1975TR","volume":"200","author":"P Barnes","year":"2019","unstructured":"Barnes P, Baker J (2019) Cellular senescence as a mechanism and target in chronic lung diseases. Am J Respir Crit Care Med 200(5):556\u2013564. https:\/\/doi.org\/10.1164\/rccm.201810-1975TR","journal-title":"Am J Respir Crit Care Med"},{"key":"4856_CR62","doi-asserted-by":"publisher","DOI":"10.3892\/IJMM.2024.5350","author":"X Zhu","year":"2024","unstructured":"Zhu X, Zhang C, Liu L, Xu L, Yao L (2024) Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway. Int J Mol Med. https:\/\/doi.org\/10.3892\/IJMM.2024.5350","journal-title":"Int J Mol Med"},{"key":"4856_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093279","author":"C Hansel","year":"2020","unstructured":"Hansel C, Jendrossek V, Klein D (2020) Cellular senescence in the lung: the central role of senescent epithelial cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21093279","journal-title":"Int J Mol Sci"},{"key":"4856_CR64","doi-asserted-by":"crossref","unstructured":"Meng J et al Targeting senescence-like fibroblasts radiosensitizes non\u2013small cell lung cancer and reduces radiation-induced pulmonary fibrosis, ncbi.nlm.nih.govJ Meng, Y Li, C Wan, Y Sun, X Dai, J Huang, Y Hu, Y Gao, B Wu, Z Zhang, K Jiang, S XuJCI insight, 2021\u2022ncbi.nlm.nih.gov, Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8675198\/","DOI":"10.1172\/jci.insight.146334"},{"key":"4856_CR65","doi-asserted-by":"crossref","unstructured":"Kotani H, Han W, Iida Y, Tanino R, Cancers KK- (2024) and undefined Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells, mdpi.comH Kotani, W Han, Y Iida, R Tanino, K Katakawa, T Okimoto, Y Tsubata, T Isobe, M HaradaCancers, 2024\u2022mdpi.com, Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.mdpi.com\/2072-6694\/16\/16\/2782","DOI":"10.3390\/cancers16162782"},{"key":"4856_CR66","doi-asserted-by":"crossref","unstructured":"Lazebnik T, Biosciences AF-M and undefined (2025) Spatio-temporal model of combining chemotherapy with senolytic treatment in lung cancer, Elsevier, Accessed: Feb. 05, 2025. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0025556424002025","DOI":"10.1016\/j.mbs.2024.109342"},{"key":"4856_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116474","author":"L Wang","year":"2024","unstructured":"Wang L (2024) Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2024.116474","journal-title":"Biomed Pharmacother"},{"key":"4856_CR68","doi-asserted-by":"publisher","unstructured":"Kamada K, Kurio N, Mouri Y, Kudo Y (2024) Combination treatment with hyaluronic acid synthesis and Bcl-2 inhibitors induces senolytic elimination of oral squamous cell carcinoma cells in vitro., J Oral Maxillofac Surg Med Pathol, Mar. https:\/\/doi.org\/10.1016\/j.ajoms.2024.09.003","DOI":"10.1016\/j.ajoms.2024.09.003"},{"key":"4856_CR69","unstructured":"Study Details | Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00364286?id=NCT00652574,NCT00385580,NCT00371254,NCT00364286,NCT00339144&rank=4#study-overview"},{"key":"4856_CR70","unstructured":"Study Details | Study of Dasatinib (BMS-354825) in Patients With Solid Tumors | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00339144?id=NCT00652574,NCT00385580,NCT00371254,NCT00364286,NCT00339144&rank=5#study-overview"},{"key":"4856_CR71","unstructured":"Study Details | Dasatinib in Resectable Malignant Pleural Mesothelioma | ClinicalTrials.gov. Accessed: Mar. 27 (2025) [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00652574?id=NCT00652574,NCT00385580,NCT00371254,NCT00364286,NCT00339144&rank=1#study-overview"},{"key":"4856_CR72","unstructured":"Study Details | A Study of Dasatinib (BMS -354825) in Patients With Advanced \u2018Triple-negative\u2019 Breast Cancer | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00371254?id=NCT00652574,NCT00385580,NCT00371254,NCT00364286,NCT00339144&rank=3#study-record-dates"},{"issue":"23","key":"4856_CR73","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","volume":"15","author":"EY Yu","year":"2009","unstructured":"Yu EY et al (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15(23):7421\u20137428. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1691","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4856_CR74","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/CAD.0B013E328361FEB0","volume":"24","author":"PW Twardowski","year":"2013","unstructured":"Twardowski PW et al (2013) A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs 24(7):743\u2013753. https:\/\/doi.org\/10.1097\/CAD.0B013E328361FEB0","journal-title":"Anticancer Drugs"},{"key":"4856_CR75","unstructured":"Study Details | Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05724329?intr=Dasatinib%20%2B%20Quercetin&cond=cancer&rank=1#study-overview"},{"key":"4856_CR76","unstructured":"Study Details | An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04733534?intr=Dasatinib%20%2B%20Quercetin&cond=cancer&rank=2#study-overview"},{"key":"4856_CR77","unstructured":"Study Details | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | ClinicalTrials.gov. Accessed: Mar. 27, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT06355037?intr=Dasatinib%20%2B%20Quercetin&cond=cancer&rank=3#study-overview"},{"key":"4856_CR78","unstructured":"Study Details | Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors | ClinicalTrials.gov. Accessed: Mar. 27 (2025) [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT06113016?intr=%20fisetin&cond=cancer&term=Senescence&rank=2#study-overview"},{"key":"4856_CR79","unstructured":"Study Details | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | ClinicalTrials.gov. Accessed: Mar. 27 (2025) [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05595499?intr=%20fisetin&cond=cancer&term=Senescence&rank=3#study-overview"},{"key":"4856_CR80","unstructured":"Kirkland JL, Tchkonia T, Zhu Y, Palmer AK, LeBrasseur NK,  Miller JD (2023) Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid (United States Patent No. US20230218617A1). https:\/\/patents.google.com\/patent\/US20230218617A1\/en"},{"key":"4856_CR81","unstructured":"Beausoleil AM,  Hudson R (2020). Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (United States Patent No. US10717722B2). https:\/\/patents.google.com\/patent\/US10717722B2\/en?oq=US10717722B2"},{"issue":"1","key":"4856_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15838-0","volume":"11","author":"Y He","year":"2020","unstructured":"He Y, Zhang X, Chang J, Kim H-N, Zhang P, Wang Y, Khan S, Liu X, Zhang X, Lv D, Song L, Li W, Thummuri D, Yuan Y, Wiegand JS, Ortiz YT, Budamagunta V, Elisseeff JH, Campisi J, Almeida M, Zheng G, Zhou D (2020) Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun 11(1):1996. https:\/\/doi.org\/10.1038\/s41467-020-15838-0","journal-title":"Nat Commun"},{"issue":"9","key":"4856_CR83","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/acs.accounts.3c00794","volume":"57","author":"J Garc\u00eda-Fleitas","year":"2024","unstructured":"Garc\u00eda-Fleitas J, Garc\u00eda-Fern\u00e1ndez A, Mart\u00ed-Centelles V, Sancen\u00f3n F, Bernardos A, Mart\u00ednez M\u00e1\u00f1ez R (2024) Chemical strategies for the detection and elimination of senescent cells. Acc Chem Res 57(9):1238\u20131253. https:\/\/doi.org\/10.1021\/acs.accounts.3c00794","journal-title":"Acc Chem Res"},{"issue":"4","key":"4856_CR84","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/cancers13040723","volume":"13","author":"VJ Carpenter","year":"2021","unstructured":"Carpenter VJ, Saleh T, Gewirtz DA (2021) Senolytics for cancer therapy: is all that glitters really gold? Cancers 13(4):723. https:\/\/doi.org\/10.3390\/cancers13040723","journal-title":"Cancers"},{"issue":"9","key":"4856_CR85","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O\u2019Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103(9):e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094","journal-title":"Haematologica"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04856-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:37:06Z","timestamp":1769762226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04856-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4856"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04856-8","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We agreed with the journal policy and provided our consent for the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"16"}}